Долгая жизнь с муковисцидозом

Coifu O, Giwercman B, Pederssen SS, et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish Cystic Fibrosis Centre. Acta Pathol Microbiol Immunol Scand 1994; 102:674-80.

459

Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; 7: CD002767.

460

Elborn JS, Prescott R, Stack B, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection of the lungs. Thorax 2000; 55: 355-8.

461

Edson RS, Terrell CL The aminoglycosides. Mayo Clin Proc 1999; 74: 519-28.

462

Prayle A, Watson A, Fortnum H, et al. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax 2010:65:654-6.

463

Adeboyeku D, Jones AL, HodsonME. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. J Cyst Fibros 2011; 10:25–30.

464

Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis – the TOPIC study: a randomised controlled trial. Lancet 2005; 365: 573-8.

465

Mirakhur A, Gallagher MJ, Ledson MJ, et al. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003; 2: 19–24.

466

Al-Aloul M, Ledson M, Walshaw MJ. Renoprotective effect of fosfomycin in the treatment of multiresistant Pseudomonas aeruginosa in CF. Thorax 2004; 59: 334-6.

467

Edson RS, Brey RH, McDonald TJ, et al. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 2004; 79: 1185-91.

468

Ramsey BW, Pepe MS, QuanJM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.

469

Mulheran M, Degg C, Burr S, et al. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated highdose aminoglycoside therapy. Antimicrob Agents Chemother 2001; 45: 2502-9.

470

Hennig S, McKay K, Vidmar S, et al. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. J Cyst Fibros 2014; 13: 428-34.

471

Conrad DJ, Stenbit AE, Zettner EM, et al. Frequency of mitochondrial 12S ribosomal RNA variants in an adult cystic fibrosis population. Pharmacogenet Genomics 2008; 18: 1095-102.

472

Price DJE, Graham Dl. Effects of large doses of colistin sulphomethate on renal function. Br Med J 1970; 4: 525-7.

473

Koch-wester J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.

474

Ledson MJ, Gallagher MJ, Cowperthwaite C, et al. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998; 12: 592-4.

475

Ramsey BW, Pepe MS, QuanJM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23–30.

476

Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13Suppl 1:S23-42.

477

Al-Aloul M, Nazareth D, Walshaw M. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. J Aerosol Med Pulm Drug Deliv 2014; 27: 299–305.

478

Harrison MJ, McCarthy M, Fleming C, et al. Inhaled versus nebulised tobramycin: a real world comparison in adult cystic fibrosis (CF). J Cyst Fibros 2014; 13: 692-8.

479

Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000; 2: CD000407

480

Scheuing N, Holl RW, Dockter G, et al. Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PloSOne2013;8:e81545.

481

Haworth CS. Impact of cystic fibrosis on bone health. Curr Opin Pulm Med 2010; 16: 616-22.

482

Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13Suppl 1:S23-42.

483

Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69.

484

Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic

485

Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69.

486

Lands LC, Stanojevic S. Oral nonsteroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database System Rev 2013; 6: CD001505.

487

Southern KW, Barker PM, Solis-Moya A, et al. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2012;11:CD002203.

488

Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303: 1707-15.

489

Hansen CR, Pressler T, Koch C, et al. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005;4:35–40.

490

McKenzie SG, Chowdhury S, Strandvik B, et al. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 2007; 42: 928-37.

491

Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-40.

492

Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012; 185: 645-52.

493

Colombo JL. Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med 2003; 9: 504-8.

494

Bradley JM, Koker P, Deng Q, et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS One 2014; 9: e106195.

495

FitzSimmons SC, Burkhart GA, Borowitz D, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997; 336: 1283-9.

496

Sinaasappel M, Stern M, Littlewood J, et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002; 1: 51–75.

497

Houwen RH, van der Doef HR Sermet I, et al. Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. J Pediatr Gastroenterol Nutr 2010; 50: 38–42.

498

McKone EF Borowitz D, Drevinek R et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med 2014; 2: 902-10.

499

NickJA, Moskowitz SM, Chmiel JF et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014; 11: 342-50.

500

Skov M, Main KM, Sillesen IB, et al. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. Eur Respir J 2002; 20: 127-33.

501

Gilchrist FJ, Cox KJ, Rowe R, et al. Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression

502

CholonDM,QuinneyNL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR'm cystic fibrosis. Sci Transl Med 2014; 6: 246ra96.

503

Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med 2014; 6: 246ra97.

504

Robinson WM, RavillyS, Berde С, et al. End of life care in patients with cystic fibrosis. Pediatrics 1997; 100:205-9.

505

Robinson WM. Palliative care and end of life care in cystic fibrosis: what we know and what we need to know. Curr Opin Pulm Med 2009; 15:621-5.

506

Sands D, Repetto T, Dupont LJ, et al. End of life care for patients with cystic fibrosis. J Cyst Fibros 2011; 10(Suppl2):S37-S44.

507

Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992–2001.

508

Smyth AR, Bell SC, Bojcin S,et al. European Cystic Fibrosis Society Standards of care: Best practice guidelines. J Cyst Fibros 2014; 13 Suppl 1:S23-42.

509

Knoop C, Dupont LJ. Cystic fibrosis. In: Fisher AJ, Verleden GM, Massard G, eds. Lung transplantation. Eur Respir Monogr; 2009; 45:32–45.

510

Corris PA. Lung transplantation for cystic fibrosis and bronchiectasis. Semin Respir Crit Care Med 2013; 34: 297–304.

511

Mitchell I, Nakielna E, Tullis E, et al. Cystic fibrosis. End stage care in Canada. Chest 2000; 118:80-4.

512

Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:335-8.

513

Bourke SJ, Doe SJ, Gascoigne AD, et al. An integrated model of provision of palliative care to patients with cystic fibrosis. Palliat Med 2009; 23: 512-7.

514

Jackson AD, Daly L, Kelleher C, et al. The application of current lifetable methods to compare cystic fibrosis median survival internationally is limited. J Cyst Fibros 2011; 10:62-5.

515

Hayes M, Yaster M, Haythornthwaite J, et al. Pain is a common problem affecting clinical outcomes in adults with cystic fibrosis. Chest 2011; 140: 1598-603.

516

Sawicki GS, Dill EJ, Asher D, et al. Advance care planning in adults with cystic fibrosis. J Palliat Med 2008; 11: 1135-41.

517

Braithwaite M, Philip J, Tranberg H, et al. End of life care in CF: patients, families and staff experiences and unmet needs. J Cyst Fibros 2011; 10:253-7.

518

Chapman AL. End of life care for adult CF patients – facilitating a good enough death. J Cyst Fibros 2005; 4: 249-57.

519

Braithwaite M, Philip J, Tranberg H, et al. End of life care in CF: patients, families and staff experiences and unmet needs. J Cyst Fibros 2011; 10:253-7.

520

Robinson W. Palliative care in cystic fibrosis. J Palliat Med 2000; 3: 187-92.

521

Stenekes SJ, Hughes A, Gregoire MC, et al. Frequency and selfmanagement of pain, dyspnea, and cough in cystic fibrosis. J Pain Symptom Manage 2009; 38: 837-48.

522

World Health Organization. WHO definition of palliative care, http://www.who.int/cancer/palliative/definition/en/ – 5 March 2014.

523

Chapman AL. End of life care for adult CF patients – facilitating a good enough death. J Cyst Fibros 2005; 4: 249-57.

524

Clisby N, Shaw S, Cormack M. Psychological impact of working with patients with cystic fibrosis at end-of-life, pre-transplant stage. Palliat Support Care 2013; 11:111-21.

525

Clisby N, Shaw S, Cormack M. Psychological impact of working with patients with cystic fibrosis at end-of-life, pre-transplant stage. Palliat Support Care 2013; 11:111-21.

526

Stenekes SJ, Hughes A, Gregoire MC, et al. Frequency and selfmanagement of pain, dyspnea, and cough in cystic fibrosis. J Pain Symptom Manage 2009; 38: 837-48.

527

Jennings AL, Davies AN, Higgins JPT, et al. A systematic review of use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-44.

528

SchwartzsteinRM,LahiveK, Pope A, et al. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis1987; 136:58–61.

529

Kallet RH. The role of inhaled opioids and furosemide for the treatment of dyspnea. Respir Care 2007; 52: 900-10.

530

Heslop K. Cognitive behavioural therapy in cystic fibrosis. J Royal Soc Med 2006; 99 (Suppl 46): 27-9.

531

Abernethy AP, McDonald CF, Firth PA, et al. Effects of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blinded randomised controlled trial. Lancet 2010; 376: 784-93.

532

Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy for chronic cough. Am J Respir Crit Care Med 2007; 175: 312-15.

533

Wee B, Browning J, Adams A, et al. Management of chronic cough in patients receiving palliative care: review of evidence and recommendations by a task group of the Association for Palliative Medicine of Great Britain and Ireland. Palliat Med 2012; 26: 780-7.

534

Sleeman KE, Collis E. Caring for a dying patient in hospital. BMJ 2013; 346: 33-7.

535

Ford D, Flume PA. Impact of lung transplantation on site of death in cystic fibrosis. J Cyst Fibros 2007; 6: 391-5.

536

Dellon EP, Leigh MW, Yankaskas JR, et al. Effects of lung transplantation on inpatient end of life care in cystic fibrosis. J Cyst Fibros 2007; 6: 396–402.

537

Hayes D Jr, Корр ВТ, Preston TJ et al. Survival of patients with cystic fibrosis on ECMO: analysis of the Extracorporeal Life Support Organization Registry. Int J Clin Exp Med 2014; 7: 1370-2.

538

Texereau J, Jamal D, Choukroun G et al. Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. Respir Res 2006;7:14–24.

539

Fauroux B, Burgel PR, Boelle PY, et al. Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. Respir Care 2008; 53: 1482-9.

540

Efrati 0, Modan-Moses D, Barak A, et al. Long-term non-invasive positive pressure ventilation among cystic fibrosis patients awaiting lung transplantation. Isr Med Assoc J 2004; 6: 527-30.

541

VedamH, MoriartyC, TorzilloPJ, et al. Improved outcomes of patient with cystic fibrosis admitted to the intensive care unit. J Cyst Fibros 2004; 3:8-14.

542

Bartz RR, Love RB, Leverson G, et al. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis. J Heart Lung Transplant 2003; 22: 433-8.

543

Elizur A, Sweet SC, Huddleston CB, et al. Pre-transplant mechanical ventilation increases shortterm morbidity and mortality in pediatric patient with cystic fibrosis. J Heart Lung Transplant 2007; 26: 127-31.

544

Perilongo G, Rigon L, Sainati L. Palliative and terminal care for dying children. Proposal for better care. Med Ped Oncol 2001; 37: 59–61.

545

Collett L, Lester D. The fear of death and the fear of dying. J Psychol 1969; 72: 179-81.

546

Besier T, Schmitz TG, Goldbeck L. Life satisfaction of adolescents and adults with cystic fibrosis: impact of partnership and gender. J Cyst Fibros 2009; 8: 104-9.

547

Badlan K. Young people living with cystic fibrosis: an insight into their subjective experience. Health Soc Care Community 2006; 14: 264-70.

548

Walters S, Britton J, Hodson ME. Demographic and social characteristics of adults with cystic fibrosis in the United Kingdom. BMJ 1993;306:549-52.

549

TargettK, BourkeS, Nash E, etal. Employment in adults with cystic fibrosis. Occup Med (Lond) 2014;64:87–94.

550

Gillen M, Lallas D, Brown C, et al. Work disability in adults with cystic fibrosis. Am J Respir Crit Care Med 1995; 152: 153-6.

551

Laborde-Casterot H, Donnay C, Chapron J, et al. Employment and work disability in adults with cystic fibrosis. J Cyst Fibros 2012; 11: 137-43.

552

Paris W, Diercks M, Bright J, et al. Return to work after lung transplantation. J Heart Lung Transplant 1998; 17: 430-6.

553

CicuttoL, BraidyC, Moloney S, et al. Factors affecting attainment of paid employment after lung transplantation. J Heart Lung Transplant 2004; 23: 481-6.

554

Burker EJ, Sedway J, Carone S, et al. Vocational attainment of adults with CF: success in the face of adversity. J Rehabil 2005, 71:22-7.

555

Burker EJ, Sedway J, Carone S, et al. Vocational attainment of adults with CF: success in the face of adversity. J Rehabil 2005, 71:22-7.

556

Frangolias DD, Holloway CL, Vedal S, et al. Role of exercise and lung function in predicting work status in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 150-7.

557

Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PloS One 2013; 8:e73322.

558

Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PloS One 2013; 8:e73322.

559

Hogg M, Braithwaite M, Bailey M, et al. Work disability in adults with cystic fibrosis and its relationship to quality of life. J Cyst Fibros 2007; 6: 223-7.

560

TargettK, BourkeS, Nash E, etal. Employment in adults with cystic fibrosis. Occup Med (Lond) 2014;64:87–94.

561

Burker EJ, Sedway J, Carone S. Psychological and educational factors: better predictors of work status than FEV, in adults with cystic fibrosis. Pediatr Pulmonol 2004;38:413-18.

562

Taylor-Robinson DC, Smyth R, Diggle PJ, et al. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PloS One 2013; 8:e73322.

563

Laborde-Casterot H, Donnay C, Chapron J, et al. Employment and work disability in adults with cystic fibrosis. J Cyst Fibros 2012; 11: 137-43.

564

Demars N, Uluer A, Sawicki GS. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil 2011; 33: 922-6.

565

Modi AC, Quittner AL, Boyle MP. Assessing disease disclosure in adults with cystic fibrosis: the Adult Data for Understanding Lifestyle and Transitions (ADULT) survey Disclosure of disease in adults with cystic fibrosis. BMC Pulm Med 2010; 10: 46.

566

Modi AC, Quittner AL, Boyle MP. Assessing disease disclosure in adults with cystic fibrosis: the Adult Data for Understanding Lifestyle and Transitions (ADULT) survey Disclosure of disease in adults with cystic fibrosis. BMC Pulm Med 2010; 10: 46.

567

Widerman E. Knowledge, interests and educational needs of adults diagnosed with cystic fibrosis after age 18. J Cyst Fibros 2003;2:97-104.

568

Demars N, Uluer A, Sawicki GS. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil 2011; 33: 922-6.

569

Demars N, Uluer A, Sawicki GS. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil 2011; 33: 922-6.

570

Edwards J, Boxall K. Adults with cystic fibrosis and barriers to employment. Disabil Soc 2010; 25: 441-53.

571

Tuchman LK, Schwartz LA, Sawicki GS, et al. Cystic fibrosis and transition to adult medical care. Pediatrics 2010; 125: 566-73.

572

Higham L, Ahmed S, Ahmed M. Hoping to live a «normal» life whilst living with unpredictable health and fear of death: impact of cystic fibrosis on young adults. J Genet Couns 2013; 22: 374-83.

573

Higham L, Ahmed S, Ahmed M. Hoping to live a «normal» life whilst living with unpredictable health and fear of death: impact of cystic fibrosis on young adults. J Genet Couns 2013; 22: 374-83.

574

Umberson D, Montez JK. Social relationships and health: a flashpoint for health policy. J Health Soc Behav 2010; 51 Suppl:S54-66.

575

Havermans T, Colpaert K, Vanharen L, et al. Health related quality of life in cystic fibrosis: to work or not to work? J Cyst Fibros 2009; 8: 218-23.

576

Havermans T, Colpaert K, Vanharen L, et al. Health related quality of life in cystic fibrosis: to work or not to work? J Cyst Fibros 2009; 8: 218-23.

577

Colpaert К Parenting with cystic fibrosis. Presented at the 32nd European Cystic Fibrosis conference. 10–13 June 2009; Brest, France. Sante Vous Bien (Adult Cystic Fibrosis Committee of Quebec). 2011;35:34-9.

578

Colpaert К Parenting with cystic fibrosis. Presented at the 32nd European Cystic Fibrosis conference. 10–13 June 2009; Brest, France. Sante Vous Bien (Adult Cystic Fibrosis Committee of Quebec). 2011;35:34-9.

579

Colpaert К Parenting with cystic fibrosis. Presented at the 32nd European Cystic Fibrosis conference. 10–13 June 2009; Brest, France. Sante Vous Bien (Adult Cystic Fibrosis Committee of Quebec). 2011;35:34-9.

580

TargettK, BourkeS, Nash E, etal. Employment in adults with cystic fibrosis. Occup Med (Lond) 2014;64:87–94.

581

Cystic Fibrosis Foundation. Patient registry annual data report 2011. Bethesda: Cystic Fibrosis Foundation; 2012. http://www.cff.org/UploadedFiles/research/ClinicalResearch/2011-Patient-Registry.pdf

582

Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry. 2011 Annual report. http://www.cysticfibrosis.ca/wp-content/uploads/2013/10/Registry2011FINALOnlineEN.pdf

583

Bellis G, Lemonnier L, Sponga M. Registre Frangais de la Mucoviscidose – Bilan des donnees 2012. Paris: Vaincre la Mucoviscidose; 2014. http://www.centre-reference-muco-lyon.fr/Registre_francais_de_mucoviscidose_2012.pdf

584

McCallum TJ, Milunsky JM, Cunningham DL, et al. Fertility in men with cystic fibrosis. An update on current surgical practices and outcome. Chest 2000; 118: 1059-62.

585

Johannesson M, Landgren BM, Csemiczky G, et al. Female patients with cystic fibrosis suffer from reproductive endocrinological disorders despite good clinical status. Hum Reprod 1998; 13: 2092-7.

586

McArdle JR. Pregnancy in cystic fibrosis. Clin Chest Med 2011; 32: 111-20.

587

Tsang A, Moriarty C, Towns S. Contraception, communication and counselling for sexuality and reproductive health in adolescents and young adults with CF. PaediatrRespir Rev 2010; 11: 84-9.